

**AMENDMENTS TO THE CLAIMS**

**Please add Claims 11-20.**

1 (previously presented): An immunohistofluorescent stain method using an anti NC1 monoclonal antibody in order to stain only kidneys of animal nephritis model and/or human nephritis but not stain normal kidneys.

2 (previously presented): An anti NC1 monoclonal antibody characterized by staining kidneys of animal nephritis model and/or human nephritis but not staining normal kidneys.

3 (previously presented): An anti NC1 monoclonal antibody characterized by immunological reaction using type IV collagen NC1 domain or its peptide (hereinafter referred to as NC1) extracted from human and/or animal renal glomeruli and both ELISA method and Western blot method.

4 (previously presented): An anti NC1 monoclonal antibody characterized by reacting with NC1 extracted from human and/or animal renal glomeruli using both ELISA method and Western blot method, and further characterized by staining only kidneys of nephritis but not staining normal kidneys as immune reaction using immunohistofluorescent stain method.

5 (previously presented): An immunologically detecting method to detect NC1 in the live specimens, wherein the anti NC1 monoclonal antibody according to claim 3 is used for detection of nephritis.

6 (previously presented): An anti NC1 antibody remover.

7 (previously presented): A NC1 remover.

8 (previously presented): A type IV collagen assay kit, wherein it consists of an anti type IV collagen antibody prepared using the renal type IV collagen as the antigen which is used for purification of the NC1 monoclonal antibody as claimed in claim 3.

9 (previously presented): An administration method, wherein it consists of higher booster dose compared to the initial dose in cases of booster administration in order to prepare an antibody and/or to vaccination.

10 (canceled)

11 (new): An anti NC1 monoclonal antibody which is capable of binding specifically to tissues of kidneys of animal nephritis models and/or human nephritis but not binding to tissues of normal kidneys.

**Int'l Appl. No. : PCT/JP2005/002669**  
**Int'l Filing Date : February 15, 2005**

12 (new): The anti NC1 monoclonal antibody according to claim 11, which is derived from immunological reaction using type IV collagen NC1 domain or its peptide (NC1) isolated from human and/or animal renal glomeruli.

13 (new): The anti NC1 monoclonal antibody according to claim 11, which is labeled with a marker.

14 (new): The anti NC1 monoclonal antibody according to claim 13, which is capable of staining renal glomerular basement membrane (GBM) of pathological sections obtained from monkey GBM antibody nephritis or human IgA nephropathy using indirect immunofluorescent stain method.

15 (new): The anti NC1 monoclonal antibody according to claim 14, which is further capable of staining other pathological sections obtained from other animal species or other human nephritis rather than IgA nephropathy.

16 (new): An NC1 detecting assay for serum and/or urine, comprising:  
an anti NC1 antibody immobilized plate;  
the marker labeled anti NC1 monoclonal antibody of claim 13;  
a coloring substrate; and  
a reaction stopper solution.

17 (new): A method of manufacturing the anti NC1 monoclonal antibody of claim 11, comprising the steps of:

extracting type IV collagen NC1 domain (NC1) from a raw material of bovine renal glomeruli;  
purifying the extract by column chromatography;  
producing monoclonal antibodies using a mouse;  
screening cell fusions and selecting positive pores with high antibody titer;  
further selecting antibodies responding to NC1 monomer and/or NC1 dimer;  
performing immunofluorescent stain to firstly select antibodies responding to monkey anti glomerular basement membrane (GBM) antibody nephritis and secondarily select antibodies not responding to normal monkey kidney; and  
thereby recovering the anti NC1 monoclonal antibody.

18 (new): An apparatus for removing an anti NC1 antibody and NC1 from blood, comprising:

**Int'l Appl. No. : PCT/JP2005/002669**

**Int'l Filing Date : February 15, 2005**

an affinity column wherein the anti NC1 monoclonal antibody of claim 11 is immobilized for dialyzing blood to remove NC1 in sera of the blood; and

an affinity column wherein an NC1 is immobilized for dialyzing the blood to remove anti NC1 antibody in sera of the blood.

19 (new): A method for removing an anti NC1 antibody and NC1 from blood, comprising the steps of:

providing the apparatus of claim 18;

dialyzing blood obtained from a subject having symptoms of nephritis to remove NC1 in sera of the blood by passing the blood through the anti NC1 monoclonal antibody-immobilized affinity column;

further dialyzing the blood to remove anti NC1 antibody in sera of the blood by passing the blood through the NC1-immobilized affinity column; and

recycling the blood from which the NC1 and the anti NC1 antibody are removed into the internal circulation of the body.

20 (new): The method according to claim 19, wherein the subject has symptoms of anti GBM antibody nephritis.